The regulator joins the EU regulator in refusing to register Leqembi, which gave similar reasons for its position on the drug ...
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
“We might be able to have a big impact.” Since January 2023, two new drug treatments — Leqembi made by Eisai and Biogen and Kisunla made by Eli Lilly — have been approved by the Food and ...
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug ...
Half of people who develop blood poisoning, otherwise known as sepsis, are dead within a couple of years, a new study finds.
A man from Kerala experienced severe body pain and fatigue upon seeking medical attention, he was diagnosed with rare ...